法国赛诺菲的喜保宁是什么药？

(Sabril) is an anti-epileptic drug. The active pharmaceutical ingredient of the drug is vigabatrin (vigabatrin). Its mechanism of action is to irreversibly inhibit GABA aminotransferase (GABA-T) and increase the concentration of GABA in the brain. France's Sanofi-Aventis is the largest pharmaceutical company in Europe and the fourth largest in the world (after Pfizer, Johnson & Johnson and GlaxoSmithKline, and higher than Merck and AstraZeneca). Sanofi Group holds leading positions in seven therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines. Sanofi's status in the field of vaccines is equivalent to GSK and its research and development of anti-cancer drugs is equivalent to Novartis. It is a well-deserved leading biopharmaceutical company in the world.

Vigabatrin is indicated as an adjunctive therapy for the treatment of adults and children (10 years and older) with refractory complex partial seizures (CPS, also known as focal seizures) who have had an inadequate response to other alternative treatments and where the potential benefits outweigh the risks of vision loss. Vigabatrin tablets are not suitable for first-line treatment of CPS. CPS, also known as temporal lobe seizures and psychomotor seizures, manifests as partial seizures accompanied by varying degrees of disturbance of consciousness. Epileptic discharges originate from the medial temporal lobe or frontal lobe, with different origins, diffusion pathways, and speeds. The clinical manifestations can vary greatly. A simple partial seizure may occur first (the duration may be long or short), and then consciousness disorder may occur. Special sensory or simple autonomic symptoms are often auras. Attacks originating from deep structures (medial temporal lobe, limbic system, etc.) such as psychotic attacks (aura) may be very short, and may cause disturbance of consciousness quickly; there may also be disturbance of consciousness at the beginning, or even a simple disturbance of consciousness. Patients can rest assured to choose Sanofi from France.

Recommended hot articles: /newsDetail/97422.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.